FDA Approves Moderna's mRNA Flu Vaccine for Older Adults

Why it matters locally: Idaho, with a significant proportion of its population aged 50 and older, will see this new vaccine become available through healthcare providers. This could offer an additional option for flu prevention in a state where agricultural workers and other outdoor professionals may have increased exposure risks.

The Food and Drug Administration (FDA) has approved Moderna's mRNA-based influenza vaccine, mFlusiva. This approval specifically covers adults aged 50 and older. mFlusiva represents a new type of flu shot entering the market. Moderna developed the vaccine using messenger RNA (mRNA) technology. This technology differs from traditional vaccine methods, which often use inactivated or weakened forms of the virus. Regulators granted approval for mFlusiva following a review of clinical data. The vaccine aims to protect against seasonal influenza. The target demographic for this shot includes individuals at higher risk of complications from the flu.